(P = .04) at independents. A number of erroneous statements were made by respondents, including that naloxone was a controlled substance, that a tablet formulation was available, and that injectable formulations not appropriate for layperson use were available.
Naloxone Accessibility Without a Prescriber Encounter Under Standing Orders at Community Pharmacy Chains in Texas
In response to the opioid overdose epidemic, each US state has passed legislation to expand access to naloxone, the opioid overdose antidote.
1 Although naloxone access laws Trained interviewers spoke to a pharmacist at each pharmacy, representing themselves as potential overdose responders (ie, third-party patients) wishing to purchase naloxone to have on hand in the event of an overdose. Interviewers used a scripted interview and a corresponding data collection instrument to obtain information regarding naloxone accessibility (Table) . To obtain the primary measure, interviewers asked: "Do I need a prescription to get naloxone or can I just come in and purchase it from you?" To ensure uniform reporting, interviewers contacted the lead author if uncertain how to document a response, and clarification was provided to all interviewers in real time. Data analysis was conducted using JMP version 13 (SAS Institute Inc). Data are presented descriptively.
Results | One pharmacist from each of the 2317 CVS, Walgreens, HEB, and Walmart pharmacies in Texas responded (100% response). The proportion of audited pharmacies in urban settings (92%; n = 2127) was similar to the overall proportion of urban Texas community pharmacies (89.6%; n = 4686).
Among audited pharmacies, 83.7% (95% CI, 82.2%-85.2%) indicated they would dispense naloxone without prescription, and 76.4% (95% CI, 74.7%-78.1%) currently stocked naloxone (Table) . Most (79.9% [95% CI, 78.3%-81.6%]) would allow purchase of naloxone for someone else, but only 49.7% (95% CI, 47.8%-51.9%) would be willing to bill the purchaser's insurance for this third-party prescription. As a marker of immediate availability, 69.4% (95% CI, 67.5%-71.2%) stocked naloxone and would dispense under standing order. Qualitatively, confusion regarding standing orders remained (eg, 40 pharmacists stated that they only applied during acute overdoses).
Discussion | The present study identified that among Texas chain pharmacies with standing orders, most stocked naloxone and would dispense it without a prescription. However, access barriers remain.
The study was limited by interviewing only 1 pharmacist per pharmacy and including only Texas chain pharmacies. These data cannot be extrapolated to independent pharmacies or areas lacking chain pharmacies.
Consistent naloxone supply in all pharmacies, improved pharmacist understanding of naloxone standing orders, and ubiquitous insurance coverage for third-party purchasers may further improve access.
1. Network for Public Health Law. Legal interventions to reduce overdose mortality: naloxone access and overdose Good Samaritan laws. What proportion of pharmacies were willing to dispense naloxone without a prescription AND currently had naloxone in stock AND were willing to bill a third party's insurance? a Specific questions asked to obtain answers 1-8: (1) "Do I need a prescription to get naloxone or can I just come in and purchase it from you?" (2) If response to question 1 was "no," caller would ask "Oh, I was at a presentation recently and they said that pharmacists at CVS, Walgreens, Walmart, and HEB have a standing order to dispense naloxone. Is your pharmacy not included in that?" (3) "Do you have naloxone in stock right now?" (4) If response to question 3 was "no," caller would ask "Are you just out of it or do you not normally carry it?" and "Would you be able to order some for me?" (5) If response to question 3 was "yes," caller would ask "Which version?" (6) "If I want to get the vial and the intramuscular syringe, am I able to buy the syringe there or do I need a prescription for that?" (7) "Even if I don't use an opioid, am I able to purchase naloxone for someone else as a precaution?" (8) "If I am getting the naloxone to use in case someone else overdoses, can I still use my own insurance to purchase the naloxone?" b This question was not specifically asked during telephone audit.
The numerator in question 9 includes stores with pharmacists answering affirmatively to both questions 1 and 3. c This question was not specifically asked during telephone audit.
The numerator in question 10 includes stores with pharmacists answering affirmatively to both question 1 and question 3 or 4. d This question was not specifically asked during telephone audit.
The numerator in question 11 includes stores with pharmacists answering affirmatively to all 3 of questions 1, 3, and 8.
https://www.networkforphl.org/_asset/qz5pvn/legal-interventions-to-reduce -overdose.pdf. Accessed June 25, 2018. 
COMMENT & RESPONSE

Guidelines on Glycemic Targets for Persons With Type 2 Diabetes
To the Editor Dr Tung and colleagues discussed the American College of Physicians (ACP) guidance statement on pharmacologic glycemic targets in adults with type 2 diabetes. 1,2 Unlike ACP guidelines, guidance statements are not based on systematic evidence reviews and do not include a formal assessment of the quality of evidence or strength of recommendation. Guidance statements are based on quality assessment of existing guidelines and rely on evidence referenced in these guidelines. We agree that the target hemoglobin A 1c (HbA 1c ) range of 7% to 8% for pharmacologic management for most individuals reflects the ACP's prioritization of balancing clinical benefits, harms, and costs. Personalizing glycemic control goals was specified as the benefits and harms of more vs less intensive glycemic control may vary according to many factors, including treatment duration, medication-specific benefits, adverse effects, and costs, as well as patient comorbidities, life expectancy, treatment adherence, and preferences.
Five large, long-term randomized trials evaluated HbA 1c targets.
2 Two that included younger individuals with newly diagnosed diabetes found benefits after more than 15 years of follow-up among individuals initially treated to an HbA 1c of 7% to 7.4% ("legacy effect"). Absolute benefits were small and microvascular event effects relied on surrogate measures. Treating younger individuals to this lower HbA 1c range is consistent with the ACP's guidance statement. There is no trial evidence that treating to an HbA 1c of less than 7% provides incremental benefit relative to the 7% to 8% range. Trials targeting HbA 1c levels below 6.5% did not improve clinical outcomes but did show significant harms, including death. Targets of less than 6.5% are appropriate for all individuals if achieved with lifestyle interventions. Tung and colleagues stated that "relaxed targets" may have unintended consequences, including difficulty in maintaining HbA 1c levels within the suggested range, safety of pharmacologic deimplementation for HbA 1c less than 6.5%, and reduced impetus for physicians to diagnose and treat previously undiagnosed disease. Their speculations are not supported by evidence. Moreover, clinical inertia works in both directions. Unnecessary intensive treatment is persistent and common and can lead to adverse effects. 3 We agree with the authors that the proper role of newer diabetes medications is an important area for future research. These medications have been associated with modest cardiovascular benefits in older individuals with established cardiovascular disease and HbA 1c levels greater than 8%, 4 but they are also costly and associated with adverse effects. Whether there is a net benefit that justifies use in younger individuals with lower HbA 1c remains to be determined.
